Physician profile
Esther Cahn
NPI 1023893815
$2,579.49
in general payments reported to CMS, 2019-2025
28 companies · $1,517 in 2025
The $1,517 reported for 2025 was more than what 89% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $113 · 2024: $949 · 2025: $1,517.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,480 · Education: $99.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,480.49 |
| Education | $99.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $295.97 | 2024-2025 | Ozempic, Rybelsus |
| Abbvie INC. | $277.23 | 2024-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $252.97 | 2024-2025 | |
| Genzyme Corporation | $218.32 | 2024-2025 | |
| Corcept Therapeutics | $165.09 | 2024-2025 | Korlym |
| Boehringer Ingelheim Pharmaceuticals, INC. | $151.73 | 2024 | Jardiance, Synjardy, Tradjenta |
| Sanofi-Aventis U.S. LLC | $113.77 | 2024-2025 | |
| Horizon Therapeutics Plc | $112.95 | 2023 | Krystexxa |
| Aimmune Therapeutics, INC. | $107.08 | 2024 | |
| Eli Lilly and Company | $99.00 | 2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $95.89 | 2024-2025 | Xifaxan |
| Glaxosmithkline, LLC. | $81.64 | 2024-2025 | Trelegy Ellipta, Arexvy |
| Astrazeneca Pharmaceuticals LP | $78.67 | 2024-2025 | Breztri |
| Amgen INC. | $66.91 | 2025 | Repatha, Otezla, Krystexxa |
| Exact Sciences Corporation | $55.76 | 2025 | Cologuard Collection Kit |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $49.80 | 2024-2025 | Capvaxive, Enflonsia |
| Globus Medical, INC. | $46.86 | 2025 | Senza |
| Lilly USA, LLC | $45.98 | 2025 | Zepbound, Mounjaro, Jardiance |
| Xeris Pharmaceuticals, INC. | $42.05 | 2025 | Gvoke Hypopen |
| Otsuka America Pharmaceutical, INC. | $40.68 | 2024-2025 | Rexulti, Abilify Maintena |
| Verona Pharma, INC. | $31.04 | 2025 | Ohtuvayre |
| Eisai INC. | $29.38 | 2025 | |
| Esperion Therapeutics, INC. | $27.40 | 2024-2025 | Nexletol |
| Paratek Pharmaceuticals, INC. | $24.12 | 2024 | Nuzyra |
| Medtronic, INC. | $18.18 | 2025 | Closurefast |
| Janssen Pharmaceuticals, INC | $17.87 | 2025 | Spravato |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $16.68 | 2025 | Caplyta |
| Vertex Pharmaceuticals Incorporated | $16.47 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Esther Cahn listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.